摘要
胃癌是常见恶性肿瘤,也是导致肿瘤相关死亡的主要病种.Her2在Her/erbB家族的活化和信号转导中起重要作用,在胃癌中的表达率为11.9%-23.7%,与胃癌Lauren分型、肿瘤发生部位及较差的长期生存有关.靶向Her2治疗方法包括单克隆抗体、小分子酪氨酸激酶抑制剂、siRNA等.ToGA研究是第一个基于Her2检测结果,将Her2单克隆抗体曲妥珠单抗联合化疗一线用于晚期胃癌治疗的Ⅲ期临床研究,并将晚期胃癌中位总生存期提升至史无前例的13.8mo;同时该研究也为胃癌分子靶向治疗带来诸多思考.
Gastric cancer is one of the most common malig-nancies and represents a major cause of cancer-related death in China.Her2 plays an impor-tant role in the activation of Her/ErbB family receptors and post-receptor signal transduction events.The rates of Her2 expression in gastric cancer range from 11.9%to 23.7%.Her2 expres-sion correlates with Laruen＇s classification,lo-cation of primary tumor,and poor outcome in gastric cancer.Her2-targeted therapeutic strate-gies include the use of monoclonal antibodies and small molecule tyrosine kinase inhibitors.ToGA study is the first phase III randomized clinical trial to evaluate the efficacy and safety of trastuzumab,an anti-Her2 monoclonal antibody,in the first-line treatment of advanced and meta-static gastric cancer.Interestingly,trastuzumab could remarkably prolong the median overall survival of patients with gastric cancer to 13.8 mo.However,this trial also triggers much con-troversy over Her2-targeted therapies for gastric cancer.
出处
《世界华人消化杂志》
CAS
北大核心
2010年第34期3648-3655,共8页
World Chinese Journal of Digestology
基金
国家自然科学基金资助项目
No.30801371~~
关键词
Her2
胃癌
靶向治疗
Her2
Gastric cancer
Targeted therapy
